ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

baloxavir

Also written as “Baloxavir Marboxil” and “Baloxavir marboxil”.

Its studies are mostly in Influenza, Human, led by 2 companies.

Drug pageBaloxavir: every studyAll 20 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Aug 10, 201810 company-led studies, 2 open or runningNext primary completion: Apr 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Rocheits history only82 open or runningphase 3since Aug 10, 2018Aug 10, 2018Apr 30, 2027phase 3 · NCT07827599
Shionogi20 open or runningphase 3since Oct 27, 2016Oct 27, 2016none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Shionogi only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Oct 27, 2016First studies: 2 phase 3 studies in Influenza, HumanFirst studyNCT02954354, NCT02949011
  2. Dec 9, 2016Named baloxavirINNProposed as its International Nonproprietary Name in WHO's List 116

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Polymerase acidic protein inhibitor; Polymerase acidic protein inhibitor”ChEMBL 37, by rule

Studies

All 2 Shionogi leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02954354Influenza, Human3CompletedApr 4, 20171,436
NCT02949011Influenza, Human3CompletedApr 12, 20182,184

How it is read

Names in the registry

  • “Baloxavir Marboxil”, 9 entries
  • “Baloxavir marboxil”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.